Assessing the Anti-Inflammatory Activity of the Anxiolytic Drug Buspirone Using CRISPR-Cas9 Gene Editing in LPS-Stimulated BV-2 Microglial Cells

Buspirone is an anxiolytic drug with robust serotonin receptor 1A (Htr1a) agonist activities. However, evidence has demonstrated that this drug also targets the dopamine D3 receptor (Drd3), where it acts as a potent antagonist. In vivo, Drd3 blockade is neuroprotective and reduces inflammation in mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas Broome, Sarah, Fisher, Teagan, Faiz, Alen, Keay, Kevin A., Musumeci, Giuseppe, Al-Badri, Ghaith, Castorina, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229595/
https://www.ncbi.nlm.nih.gov/pubmed/34070429
http://dx.doi.org/10.3390/cells10061312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229595/
https://www.ncbi.nlm.nih.gov/pubmed/34070429
http://dx.doi.org/10.3390/cells10061312

Ejemplares similares